LULULEMON/UN-FOUNDATION
lululemon and the United Nations Foundation today announced their partnership around an innovative program to address the mental and physical health of UN development and humanitarian workers who serve on the front lines of urgent global challenges, so they can better support communities around the world. lululemon will commit $1 million USD over the next three years to Peace on Purpose, an evidence-based program, which provides access to mindfulness and self-care tools and resources for UN workers to build resilience in the face of adversity and stressful environments – such as responding to humanitarian emergencies, supporting communities facing poverty, and more. Peace on Purpose's mission is to equip aid workers with the tools to care for themselves so they can effectively care for others.
“lululemon and the UN Foundation share a commitment to building community and developing collaborative solutions for some of the world’s most pressing issues,” said Calvin McDonald, CEO of lululemon. “With increasing need for international humanitarian aid and peacekeeping, we want to cultivate the long-lasting benefits of mindfulness tools and sustain support for those whose mission is to serve others.”
“UN workers are on the front lines of global challenges, helping people in their times of greatest need,” said Kathy Calvin, President and CEO of the UN Foundation. “This work can often be stressful, and the UN has made it a priority to address the well-being of its people. Innovative partnerships like Peace on Purpose can support the UN workers who support the world. With lululemon’s support, we will be able to grow the program to help more UN staff care for themselves and for others.”
Peace on Purpose is a result of a three-year pilot led by lululemon’s Here to Be team and the UN Foundation, developed to address a series of issues, such as burnout, compassion fatigue, and stress-related physical, mental, and relational effects reported by UN staff members. Peace on Purpose has worked with UN agencies to build out trainings and workshops for more than 650 staff in US headquarters and seven additional countries – Jordan, Lebanon, Pakistan, South Sudan, Turkey, Turkmenistan and Zimbabwe.
Research that followed select trainings found that over half of the participants experienced a more than 40 percent improvement in overall well-being as seen in key psychological risk factors, such as work-related self-compassion, anxiety and depression, symptoms related to trauma, and feelings of distress.
Humanitarian aid workers report experiencing high rates of burnout, stress, and mental health stigmas in difficult global settings. Peace on Purpose’s curriculum introduces mindfulness tools as well-being resources to support current UN mental health programs. These tools – such as mindful breaths, emotion regulation, and yoga – can be implemented to meet the varying needs of UN staff in the diverse environments in which they operate.
With lululemon’s continued funding commitment and thought partnership, Peace on Purpose will aim to train 3,000 more UN development and humanitarian workers in-person over the next three years, build a hub of digital resources, and develop condensed trainings and curriculum translations to reach an additional 30,000 UN staff.
Peace on Purpose is a key element of lululemon’s commitment to social impact and sustainability. The company’s Impact Agenda is comprised of three elements – Be Human, Be Well and Be Planet – to support and accelerate meaningful positive impact around the world.
To learn more about Peace on Purpose or lululemon’s Global Impact Agenda, including Here to Be, visit https://shop.lululemon.com/story/sustainability .
About lululemon athletica inc.
lululemon athletica inc. (NASDAQ:LULU) is a healthy lifestyle inspired athletic apparel company for yoga, running, training, and most other sweaty pursuits, creating transformational products and experiences which enable people to live a life they love. Setting the bar in technical fabrics and functional designs, lululemon works with yogis and athletes in local communities for continuous research and product feedback. For more information, visit www.lululemon.com
.
About the United Nations Foundation
The United Nations Foundation acts as a strategic partner to help the United Nations mobilize the ideas, people, and resources it needs to drive global progress and tackle urgent challenges. We focus on issues at the heart of the Sustainable Development Goals, build initiatives across sectors to solve problems at scale, and engage citizens who seek action. Founded in 1998 by entrepreneur and philanthropist Ted Turner, the UN Foundation works with philanthropic, corporate, government, and individual partners. Learn more at www.unfoundation.org
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191008005308/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd Announce Strategic Collaboration for the Development of Inhaled Lung Cancer Treatment2.12.2025 14:30:00 CET | Press release
CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development and clinical validation of innovative treatments of pulmonary diseases by inhalation, and Merxin Ltd, a designer and supplier of inhaler devices, have entered a strategic collaboration to develop a pioneering inhaled genetic therapy targeting lung cancer. The partnership draws upon CorriXR’s proprietary CRISPR-based gene editing platform targeting NRF2, InhaTarget’s proprietary formulation platform and strong experience in pulmonary drug development, and Merxin Ltd’s advanced inhalation device technology. Through their combined expertise, they aim to create a patient-friendly inhaled therapy that delivers targeted treatment directly to lung tumors, maximizing efficacy, minimizing systemic side effects, and offering new hope for patients facing one of the world’s deadliest cancers. Innovativ
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies2.12.2025 14:00:00 CET | Press release
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology,today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL). “We are very encouraged by the early results of the first two cohorts from our Phase 1 study of AUR112,” said Dr. Murali Ramachandra, CEO. “AUR112 has shown a promising initial clinical profile, achieving an overall response rate of 63.6% in the efficacy-evaluable population and 58.3% in the intent-to-treat group. These strong early data, combined with its distinct preclinical and safety characteristics, reinforce our belief that AUR112 has the potential to become
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer2.12.2025 14:00:00 CET | Press release
Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at ESMO 2025 The Phase 2 expansion will evaluate 160 MBq and 200 MBq doses of ADVC001 using a randomized, multi-dose-response design and adaptive dosing strategies to optimize clinical outcomes across three indications: metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC) in pre-chemotherapy and post-177Lu-PSMA radioligand therapy (RLT) settings AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) evaluating its lead investigational candidate, ADVC001, in metastatic prostate cancer. The news follows the encouraging Phase 1b dose escalation results presented at the European Society for Medical Oncology (ESMO) 2025 congress that showed a favorable safety profile and compelling
Luma AI Opens for International Business With Former WPP Executive Jason Day Leading New London Office2.12.2025 14:00:00 CET | Press release
Establishment of the London office follows Luma AI’s $900 million Series C investment led by HUMAIN - marking the company’s first major step towards international scale with plans to deepen partnerships across the UK, European Union, and Saudi Arabia in the first phase of expansion.Former Monks and WPP executive Jason Day was appointed Head of EMEA to launch Luma AI internationally and drive worldwide growth across creative, advertising, gaming, and entertainment sectors.Luma AI plans to add 200 new jobs in London in 2026. Luma AI, the frontier artificial intelligence company building multimodal AGI intelligence and known for its flagship product Dream Machine, today announced a major step in its global expansion with the opening of its first international office in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202217704/en/ LUMA AI OPENS FOR INTERNATIONAL BUSINESS WITH FORMER WPP EXECUTIVE JASON DAY LEADING
Eventbrite Enters into Definitive Agreement to Be Acquired by Bending Spoons for Roughly $500 Million to Accelerate Eventbrite’s Next Phase of Growth2.12.2025 13:30:00 CET | Press release
Eventbrite stockholders to receive $4.50 per share in cash Eventbrite, Inc. (NYSE: EB), the leading global marketplace for shared experiences, announced today that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all-cash transaction valued at approximately $500 million. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals and approval by Eventbrite’s stockholders. “For two decades, Eventbrite has stood at the forefront of the experience economy, helping tens of millions to create, discover, and attend unforgettable events,” said Luca Ferrari, Bending Spoons CEO and Co-Founder. “Joining forces with Bending Spoons will accelerate innovation and strengthen Eventbrite’s tools and resources to bring even more people together through shared live experiences for many years to come. As longstanding fans, we’ve identified a few opportunities that we’re excited about exploring with the Eventbrite team after cl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom